VBS

VECTUS BIO FPO [VBS]
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia.
Healthcare · ASX Small Cap
$0.1950 +11.4%

Updated 14 Jul 2026 · Signals refresh every scan

Get alerts when VBS triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track VBS — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Pressing against the upper Bollinger Band — extended and may need to cool off
  • Trading above both moving averages — the trend is your friend here
  • Above-average volume (1.5x) on a green day — buyers stepping up
  • Just broke above 20-day resistance — a level that was capping price, now cleared
  • On a tear — up 39.3% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.40, so it's outpacing the pack
  • Volatility is expanding fast — choppy price action, so buckle up
  • Trading above the 200-day average — the long-term trend is on your side
  • Critical cash runway (1.6 quarters)
  • Very high P/S ratio (123.4x)
  • Revenue in sharp decline (-99%)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (1 events)
  • CANSLIM S: Tight float (40%)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 150% over the past year (excluding last month)
  • Excellent risk-adjusted returns — Sharpe of 1.6 means strong gains without wild swings
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.42%/day)
  • RBA hiking (-3pts)
  • Dilution risk: technical breakout with recent capital raise

Risk Signals

  • RSI is running hot — overbought territory, so expect some pullback risk
  • Stochastic is stretched into overbought — could need a breather
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -99% — the top line is shrinking
Ask Scout AI about VBS
"What's driving VBS today?" "How does VBS compare to peers?" "Key risks for VBS?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE VBS Engages CHRS as Regulatory Agent for FDA Submissions
NONE Cleansing Notice
NONE Application for quotation of securities - VBS
Announcement tone +5pts

Recent ASX Announcements

2026-07-12 VBS Engages CHRS as Regulatory Agent for FDA Submissions
2026-06-26 Cleansing Notice
2026-06-26 Application for quotation of securities - VBS
2026-06-16 CEO Investor Webinar
2026-05-29 Change in substantial holding

Key Metrics

$11.1M
Market Cap
47K
Avg Volume
1.5x
Vol Ratio
$0.04 — $0.46
52-Week Range
N/A
Short Interest
N/A
Cash Runway
N/A
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 40%
LLeader vs LaggardpassRS: 26
IInstitutional SponsorshipweakInst: 6%
MMarket DirectionneutralNeutral

Sector: Healthcare

109 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS -20.0%MEM -12.5%NTI +12.5%BDX +11.0%MAP -9.8%
Compare:VBS vs ECSVBS vs MEMVBS vs NTI
Scout Pro — Deeper Analysis for VBS
Try Pro free for 30 days
Share this analysis

Track VBS and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required